Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: Differential effects at different time points

U. N. Verma, A. Mazumder

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

IL-12 augments many effector functions associated with T and NK cells including induction of cytotoxic activity and secretion of various cytokines. In addition, synergistic responses with IL-2 in most of the functions attributed to that cytokine make IL-12 an attractive candidate to have a potential role as an immunotherapeutic agent. We have evaluated the effect of rhIL-12 either alone or in combination with IL-2 on the generation of cytotoxic effecters from normal human bone marrow. IL-12 induced cytotoxic effecters against NK sensitive targets within 24 h of stimulation and this activity was maintained in cultures with IL-12 supplementation for up to 2 weeks tested. The decline in NK activity seen in control cultures over a period of 2 weeks was thus not observed in IL-12 stimulated cultures. In addition, a small increase was also observed in cytotoxic activity against NK resistant Daudi cell targets. IL-12, when combined with a low to intermediate dose of IL-2, led to enhancement in IL-2 induced cytotoxicity against both NK sensitive and resistant targets. However an increase in cytotoxicity against NK resistant targets was evident only after 1 week of stimulation. Cellular yield and number of hematopoietic precursors (LTC-IC, CFU-GM, BFU-e) in IL-12 stimulated cultures was comparable to or higher than control cultures at all the three time points (days 1, 7, 14) tested. In contrast, cultures stimulated with a combination of IL-12/IL-2 showed an increased number of hematopoietic precursors at day 1 followed by a marked decrease in the number of these precursors at day 7 and day 14. The several-fold higher levels of inhibitory cytokines such as IFN-γ and TNF-β detected in these combination cultures may be responsible for this biphasic behavior of hematopoietic precursors in combination cultures. Thus, IL-12 has differential effects alone or in combination with IL-2 on lymphoid and myeloid cells.

Original languageEnglish (US)
Pages (from-to)365-372
Number of pages8
JournalBone Marrow Transplantation
Volume16
Issue number3
StatePublished - 1995

Fingerprint

Interleukin-12
Interleukin-2
Bone Marrow
Cytokines
In Vitro Techniques
Granulocyte-Macrophage Progenitor Cells
Myeloid Cells
Natural Killer Cells
Lymphocytes
T-Lymphocytes

Keywords

  • Anti-tumor cytotoxicity
  • Hematopoietic progenitors
  • IL-12
  • IL-2

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{f36e333b75ff47b5b2b62e770c4ede4c,
title = "Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: Differential effects at different time points",
abstract = "IL-12 augments many effector functions associated with T and NK cells including induction of cytotoxic activity and secretion of various cytokines. In addition, synergistic responses with IL-2 in most of the functions attributed to that cytokine make IL-12 an attractive candidate to have a potential role as an immunotherapeutic agent. We have evaluated the effect of rhIL-12 either alone or in combination with IL-2 on the generation of cytotoxic effecters from normal human bone marrow. IL-12 induced cytotoxic effecters against NK sensitive targets within 24 h of stimulation and this activity was maintained in cultures with IL-12 supplementation for up to 2 weeks tested. The decline in NK activity seen in control cultures over a period of 2 weeks was thus not observed in IL-12 stimulated cultures. In addition, a small increase was also observed in cytotoxic activity against NK resistant Daudi cell targets. IL-12, when combined with a low to intermediate dose of IL-2, led to enhancement in IL-2 induced cytotoxicity against both NK sensitive and resistant targets. However an increase in cytotoxicity against NK resistant targets was evident only after 1 week of stimulation. Cellular yield and number of hematopoietic precursors (LTC-IC, CFU-GM, BFU-e) in IL-12 stimulated cultures was comparable to or higher than control cultures at all the three time points (days 1, 7, 14) tested. In contrast, cultures stimulated with a combination of IL-12/IL-2 showed an increased number of hematopoietic precursors at day 1 followed by a marked decrease in the number of these precursors at day 7 and day 14. The several-fold higher levels of inhibitory cytokines such as IFN-γ and TNF-β detected in these combination cultures may be responsible for this biphasic behavior of hematopoietic precursors in combination cultures. Thus, IL-12 has differential effects alone or in combination with IL-2 on lymphoid and myeloid cells.",
keywords = "Anti-tumor cytotoxicity, Hematopoietic progenitors, IL-12, IL-2",
author = "Verma, {U. N.} and A. Mazumder",
year = "1995",
language = "English (US)",
volume = "16",
pages = "365--372",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow

T2 - Differential effects at different time points

AU - Verma, U. N.

AU - Mazumder, A.

PY - 1995

Y1 - 1995

N2 - IL-12 augments many effector functions associated with T and NK cells including induction of cytotoxic activity and secretion of various cytokines. In addition, synergistic responses with IL-2 in most of the functions attributed to that cytokine make IL-12 an attractive candidate to have a potential role as an immunotherapeutic agent. We have evaluated the effect of rhIL-12 either alone or in combination with IL-2 on the generation of cytotoxic effecters from normal human bone marrow. IL-12 induced cytotoxic effecters against NK sensitive targets within 24 h of stimulation and this activity was maintained in cultures with IL-12 supplementation for up to 2 weeks tested. The decline in NK activity seen in control cultures over a period of 2 weeks was thus not observed in IL-12 stimulated cultures. In addition, a small increase was also observed in cytotoxic activity against NK resistant Daudi cell targets. IL-12, when combined with a low to intermediate dose of IL-2, led to enhancement in IL-2 induced cytotoxicity against both NK sensitive and resistant targets. However an increase in cytotoxicity against NK resistant targets was evident only after 1 week of stimulation. Cellular yield and number of hematopoietic precursors (LTC-IC, CFU-GM, BFU-e) in IL-12 stimulated cultures was comparable to or higher than control cultures at all the three time points (days 1, 7, 14) tested. In contrast, cultures stimulated with a combination of IL-12/IL-2 showed an increased number of hematopoietic precursors at day 1 followed by a marked decrease in the number of these precursors at day 7 and day 14. The several-fold higher levels of inhibitory cytokines such as IFN-γ and TNF-β detected in these combination cultures may be responsible for this biphasic behavior of hematopoietic precursors in combination cultures. Thus, IL-12 has differential effects alone or in combination with IL-2 on lymphoid and myeloid cells.

AB - IL-12 augments many effector functions associated with T and NK cells including induction of cytotoxic activity and secretion of various cytokines. In addition, synergistic responses with IL-2 in most of the functions attributed to that cytokine make IL-12 an attractive candidate to have a potential role as an immunotherapeutic agent. We have evaluated the effect of rhIL-12 either alone or in combination with IL-2 on the generation of cytotoxic effecters from normal human bone marrow. IL-12 induced cytotoxic effecters against NK sensitive targets within 24 h of stimulation and this activity was maintained in cultures with IL-12 supplementation for up to 2 weeks tested. The decline in NK activity seen in control cultures over a period of 2 weeks was thus not observed in IL-12 stimulated cultures. In addition, a small increase was also observed in cytotoxic activity against NK resistant Daudi cell targets. IL-12, when combined with a low to intermediate dose of IL-2, led to enhancement in IL-2 induced cytotoxicity against both NK sensitive and resistant targets. However an increase in cytotoxicity against NK resistant targets was evident only after 1 week of stimulation. Cellular yield and number of hematopoietic precursors (LTC-IC, CFU-GM, BFU-e) in IL-12 stimulated cultures was comparable to or higher than control cultures at all the three time points (days 1, 7, 14) tested. In contrast, cultures stimulated with a combination of IL-12/IL-2 showed an increased number of hematopoietic precursors at day 1 followed by a marked decrease in the number of these precursors at day 7 and day 14. The several-fold higher levels of inhibitory cytokines such as IFN-γ and TNF-β detected in these combination cultures may be responsible for this biphasic behavior of hematopoietic precursors in combination cultures. Thus, IL-12 has differential effects alone or in combination with IL-2 on lymphoid and myeloid cells.

KW - Anti-tumor cytotoxicity

KW - Hematopoietic progenitors

KW - IL-12

KW - IL-2

UR - http://www.scopus.com/inward/record.url?scp=0029166825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029166825&partnerID=8YFLogxK

M3 - Article

C2 - 8535308

AN - SCOPUS:0029166825

VL - 16

SP - 365

EP - 372

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -